A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)
Stopped early · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis, AD
In brief
The primary objective of this study is to evaluate the safety of IMG-007 in adults with moderate-to-severe AD. The secondary objectives are to evaluate the pharmacokinetics and efficacy of IMG-007 in AD patients.
Key facts
- Study ID
- NCT05984784
- Run by
- Inmagene LLC
- People needed
- 13
- Starts
- 2023-08-09
- Expected to finish
- 2024-04-26
- Last updated by the study team
- 2025-11-06
Who can join
Age: 18 and older, up to 74. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Amicis Research Center — Northridge, California, United States
- Amicis Research Center — Valencia, California, United States
- Medical Research Center of Miami II Inc — Miami, Florida, United States
- Optimal Research Sites — Orange City, Florida, United States
- USF Carol and Frank Morsani Center for Advanced Healthcare — Tampa, Florida, United States
- Revival Research Institute, LLC — Troy, Michigan, United States
- Markowitz Medical, LLC — New York, New York, United States
- Central Sooner Research — Oklahoma City, Oklahoma, United States
- Paddington Testing Co, Inc — Philadelphia, Pennsylvania, United States
- Brunswick Dermatology Center — Fredericton, New Brunswick, Canada
- DermEffects — London, Ontario, Canada
- Centre de Recherche Saint-Louis (Québec) — Québec, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.